Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 110, Issue 3, 2015, Pages 250-256

  Aso, Yoshimasa ^a   Fukushima, Maiko ^b   Sagara, Masaaki ^a   Jojima, Teruo ^a   Iijima, Toshie ^a   Suzuki, Kunihiro ^a   Momobayashi, Atsushi ^b   Kasai, Kikuo ^c   Inukai, Toshihiko ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b LSI MEDIENCE CORPORATION   (Japan)

^c Ishibashi General Hospital   (Japan)

Author keywords

CD4+ T cell; DPP 4 inhibitor; Regulatory T cell; T helper 17 cell

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; GAMMA INTERFERON; GLIMEPIRIDE; HEMOGLOBIN A1C; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; SITAGLIPTIN; TRANSCRIPTION FACTOR FOXP3; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; IFNG PROTEIN, HUMAN; IL17A PROTEIN, HUMAN; IL4 PROTEIN, HUMAN; SULFONYLUREA DERIVATIVE;

AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GLYCEMIC CONTROL; HIGH RISK POPULATION; HUMAN; HUMAN CELL; INFECTION RISK; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; TREATMENT DURATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

AGED; CD4-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; FLOW CYTOMETRY; HUMANS; HYPOGLYCEMIC AGENTS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-4; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SITAGLIPTIN PHOSPHATE; SULFONYLUREA COMPOUNDS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84955139644     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.10.012     Document Type: Article

References (38)

1. Ohnuma K., Hosono O., Dang N.H., Morimoto C. Dipeptidyl peptidase in autoimmune pathophysiology. Adv Clin Chem 2011, 53:51-84.
2. Lambeir A.M., Durinx C., Scharpé S., De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003, 40:209-294.
3. Morimoto C., Schlossman S.F. The structure and function of CD26 in the T-cell immune response. Immunol Rev 1998, 161:55-70.
4. Tanaka T., Camerini D., Seed B., Torimoto Y., Dang N.H., Kameoka J., et al. Cloning and functional expression of the T cell activation antigen CD26. J Immunol 1992, 149:481-486.
5. Bengsch B., Seigel B., Flecken T., Wolanski J., Blum H.E., Thimme R. Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). J Immunol 2012, 188:5438-5447.
6. Iwaki-Egawa S., Watanabe Y., Kikuya Y., Fujimoto Y. Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence. J Biochem 1998, 124:428-433.
7. Durinx C., Lambeir A.M., Bosmans E., Falmagne J.B., Berghmans R., Haemers A., et al. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 2000, 267:5608-5613.
8. Tanaka T., Duke-Cohan J.S., Kameoka J., Yaron A., Lee I., Schlossman S.F., et al. Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV. Proc Natl Acad Sci U S A 1994, 91:3082-3086.
9. Kim W., Egan J.M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008, 60:470-512.
10. Aso Y., Ozeki N., Terasawa T., Naruse R., Hara K., Suetsugu M., et al. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Transl Res 2012, 159:25-31.
11. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194-206.
12. Richter B., Bandeira-Echtler E., Bergerhoff K., Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008, 4:753-768.
13. Williams-Herman D., Round E., Swern A.S., Musser B., Davies M.J., Stein P.P., et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord 2008, 8:14.
14. Aso Y., Terasawa T., Kato K., Jojima T., Suzuki K., Iijima T., et al. The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes. Transl Res 2013, 162:309-316.
15. Dang N.H., Torimoto Y., Shimamura K., Tanaka T., Daley J.F., Schlossman S.F., et al. 1F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation. J Immunol 1991, 147:2825-2832.
16. Ruiz P., Zacharievich N., Hao L., Viciana A.L., Shenkin M. Human thymocyte dipeptidyl peptidase IV (CD26) activity is altered with stage of ontogeny. Clin Immunol Immunopathol 1998, 88:156-168.
17. Yu D.M., Slaitini L., Gysbers V., Riekhoff A.G., Kähne T., Knott H.M., et al. Soluble CD26/dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding. Scand J Immunol 2011, 73:102-111.
18. Yan S., Marguet D., Dobers J., Reutter W., Fan H. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur J Immunol 2003, 33:1519-1527.
19. Jagannathan-Bogdan M., McDonnell M.E., Shin H., Rehman Q., Hasturk H., Apovian C.M., et al. Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J Immunol 2011, 186:1162-1172.
20. Noack M., Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014, 13:668-677.
21. Winer S., Paltser G., Chan Y., Tsui H., Engleman E., Winer D., et al. Obesity predisposes to Th17 bias. Eur J Immunol 2009, 39:2629-2635.
22. Zhao Y.1., Yang L., Wang X., Zhou Z. The new insights of DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes. Diabetes Metab Res Rev 2014, [Epub ahead of print]. 10.1002/dmrr.2530.
23. Mallat Z., Ait-Oufella H., Tedgui A. Regulatory T-cell immunity in atherosclerosis. Trends Cardiovasc Med 2007, 17:113-118.
24. Wagner N.M., Brandhorst G., Czepluch F., Lankeit M., Eberle C., Herzberg S., et al. Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk. Obesity (Silver Spring) 2013, 21:461-468.
25. Price J.D1, Linder G., Li W.P., Zimmermann B., Rother K.I., Malek R., et al. Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study. Clin Exp Immunol 2013, 174:120-128.
26. Sasaki T., Hiki Y., Nagumo S., Ikeda R., Kimura H., Yamashiro K., et al. Acute onset of rheumatoid arthritis associated with administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor to patients with diabetes mellitus. Diabetol Int 2010, 1:90-92.
27. Saito T., Ohnuma K., Suzuki H., Dang N.H., Hatano R., Ninomiya H., et al. Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors. Diabetes Res Clin Pract 2013, 102:e8-e12.
28. Crickx E., Marroun I., Veyrie C., Le Beller C., Schoindre Y., Bouilloud F., et al. DPP4 inhibitor-induced polyarthritis: a report of three cases. Rheumatol Int 2014, 34:291-292.
29. Nistala K., Wedderburn L.R. Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. Rheumatology (Oxf) 2009, 48:602-606.
30. Alunno A., Manetti M., Caterbi S., Ibba-Manneschi L., Bistoni O., Bartoloni E., et al. Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications. Mediators Inflamm 2015, 2015:751793.
31. Tasic T., Bäumer W., Schmiedl A., Schwichtenhövel F., Pabst R., Raap U., et al. Dipeptidyl peptidase IV (DPP4) deficiency increases Th1-driven allergic contact dermatitis. Clin Exp Allergy 2011, 41:1098-1107.
32. Schmiedl A., Krainski J., Schwichtenhövel F., Schade J., Klemann C., Raber K.A., et al. Reduced airway inflammation in CD26/DPP4-deficient F344 rats is associated with altered recruitment patterns of regulatory T cells and expression of pulmonary surfactant proteins. Clin Exp Allergy 2010, 40:1794-1808.
33. Cheng X., Yu X., Ding Y.J., Fu Q.Q., Xie J.J., Tang T.T., et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 2008, 127:89-97.
34. Zhu J., Paul W.E. Heterogeneity and plasticity of T helper cells. Cell Res 2010, 20:4-12.
35. Makdissi A1, Ghanim H., Vora M., Green K., Abuaysheh S., Chaudhuri A., et al. Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab 2012, 97:3333-3341.
36. White P.C., Chamberlain-Shea H., de la Morena M.T. Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation. J Diabetes Complications 2010, 24:209-213.
37. Anz D., Kruger S., Haubner S., Rapp M., Bourquin C., Endres S. The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses. Diabetes Obes Metab 2014, 16:569-572.
38. van Poppel P.C., Gresnigt M.S., Smits P., Netea M.G., Tack C.J. The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2014, 103:395-401.